{
  "slug": "lycopene",
  "name": "Lycopene (Tomato Carotenoid)",
  "alternate_names": [
    "All-trans-lycopene",
    "Tomato lycopene",
    "Synthetic lycopene"
  ],
  "mechanism": [
    "Acyclic carotenoid with strongest singlet oxygen quenching among the carotenoid family",
    "Modulates oxidative stress markers in serum (varies by study)",
    "Heat-processed tomato matrices increase bioavailability vs raw tomato"
  ],
  "target": [
    "Serum oxidative stress markers",
    "Prostate tissue carotenoid pool (mechanism interest only · no QHC support)"
  ],
  "use_case": [
    "general carotenoid dietary diversity",
    "tomato-derived antioxidant adjunct"
  ],
  "body_system": [
    "CELL"
  ],
  "evidence_tier": "C",
  "evidence_anchor_pmid_count": 1,
  "dosage_range": "Typical commercial product 10-30 mg/day from tomato extract. Kavanaugh 2007 PMID 17623802 JNCI summarises the FDA evidence-based review of qualified health claim petitions for tomatoes / lycopene + cancer (prostate / lung / colorectal / gastric / breast / ovarian / endometrial / pancreatic) — FDA concluded there is no credible evidence to support a lycopene-cancer association and only very limited evidence for tomato consumption + a narrow set of cancer sites",
  "safety_notes": "Excellent safety profile within typical supplement doses. Very-high-dose lycopene can produce orange-tinted skin (lycopenodermia) — reversible and not harmful",
  "regulatory": {
    "fda": "GRAS · DSHEA dietary supplement · NO authorized cancer-risk-reduction claim (2005 FDA QHC petition denied for lycopene-cancer); structure/function claims permitted",
    "efsa": "No EFSA Reg 432/2012 authorized health claim adopted for lycopene; some opinions remain inconclusive",
    "anvisa": "RDC 243/2018 dietary supplement · no IN 28/2018 Anexo V alegação funcional for licopeno"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/lycopene/",
  "related_goal_slugs": [
    "heart-health",
    "longevity-stack"
  ],
  "related_lifestyle_slugs": [
    "plant-based"
  ],
  "last_evidence_review": "2026-06-04",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-04",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}